ProQR (PRQR) Stock Price & Analysis


PRQR Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$0.53 - $3.85
Previous Close$2.52
Average Volume (3M)1.20M
Market Cap
Enterprise Value$94.52M
Total Cash (Recent Filing)€100.43M
Total Debt (Recent Filing)€22.22M
Price to Earnings (P/E)-2.3
May 10, 2023
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.08
Shares Outstanding71,434,624
10 Day Avg. Volume1,213,224
30 Day Avg. Volume1,199,013
Standard Deviation0.39
Financial Highlights & Ratios
Price to Book (P/B)3.84
Price to Sales (P/S)81.15
Price to Cash Flow (P/CF)N/A
P/FCF Ratio-4.80
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Price Target Upside124.52% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3



Risk Analysis

Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.



What was ProQR’s price range in the past 12 months?
ProQR lowest stock price was $0.53 and its highest was $3.85 in the past 12 months.
    What is ProQR’s market cap?
    Currently, no data Available
    When is ProQR’s upcoming earnings report date?
    ProQR’s upcoming earnings report date is May 10, 2023 which is in 41 days.
      How were ProQR’s earnings last quarter?
      Currently, no data Available
      Is ProQR overvalued?
      According to Wall Street analysts ProQR’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
        Does ProQR pay dividends?
        ProQR does not currently pay dividends.
        What is ProQR’s EPS estimate?
        ProQR’s EPS estimate for its next earnings report is not yet available.
        How many shares outstanding does ProQR have?
        ProQR has 71,290,800 shares outstanding.
          What happened to ProQR’s price movement after its last earnings report?
          Currently, no data Available
          Which hedge fund is a major shareholder of ProQR?
          Among the largest hedge funds holding ProQR’s share is Gilder Gagnon Howe & Co LLC.. It holds ProQR’s shares valued at 359K.


            ProQR Stock Smart Score

            The ProQR stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
            Learn more about TipRanks Smart Score

            Company Description


            ProQR Therapeutics NV operates as a biopharmaceutical company, which engages in the discovery and development of Ribonucleic Acid RNA based therapeutics for the treatment of genetic disorders. Its initial focus is on the development of a disease-modifying therapy for the treatment of cystic fibrosis. The company was founded by Daniel de Boer, Gerard Platenburg, Henri Termeer and Dinko Valerio on February 21, 2012 and is headquartered in Leiden, the Netherlands.


            Top 5 ETFs holding PRQR

            Currently, no data available
            Please return soon. This page is being updated.
            Up to five ETFs with an Outperform Smart Score that hold PRQR. The ETFs are listed according to market value of PRQR within the ETF


            Forecast EPS vs Actual EPS

            Currently, no data available
            Please return soon. This page is being updated.

            Similar Stocks
            Price & Change
            LAVA Therapeutics
            Vertex Pharmaceuticals

            Popular Stocks

            What's Included in PREMIUM?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis